Free Newsletter
EMEA panel backs Lilly's prasugrel
Good news for Eli Lilly. While Lilly was holding its breath for a response from the FDA for its experimental drug, prasugrel, the company managed to gain an endorsement from an EMEA advisory panel. The committee's recommendation will go to the European Commission, which usually makes a decision in two to three months, according to partners Lilly and Daiichi Sankyo.
Prasugrel, which will be marketed under the brand name Effient, is a blood thinner designed to fight clots in heart disease and stroke patients. The much-watched drug has been touted by analysts as a potential blockbuster. Data from a three-year study involving 13,608 patients showed that Lilly's prasugrel outperformed its top competitor, Plavix, but also presented an increased risk of bleeding.
Lilly submitted its application to the FDA last December. The agency gave the NDA priority review, which is designed to ensure a decision within 6 months, rather than the typical 10 months. But the FDA has delayed its review twice--in June and again in September.
- view the Eli Lilly/Daiichi Sankyo release
- check out the IndyStar's report for more
Related Articles:
Daiichi, Lilly: still no word on prasugrel
Deadline clock running on Lilly's next big blockbuster
Biopharma sees tougher FDA approval process
Dry spell or parched desert for NME approvals?
2008 NME approvals no better than last year?
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





